Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $280,300.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 10,000 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $28.03, for a total value of $280,300.00. Following the transaction, the chief operating officer now directly owns 218,083 shares in the company, valued at approximately $6,112,866.49. The trade was a 4.38 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Jonathan Young also recently made the following trade(s):

• On Tuesday, December 10th, Jonathan Young sold 2,503 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.79, for a total value of $77,067.37.
• On Monday, December 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.13, for a total value of $321,300.00.
• On Friday, November 1st, Jonathan Young sold 50,716 shares of Akero Therapeutics stock. The stock was sold at an average price of $31.57, for a total transaction of $1,601,104.12.
• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.15, for a total transaction of $1,206,000.00.

Akero Therapeutics Stock Down 3.7 %

AKRO stock opened at $26.61 on Wednesday. The stock has a market capitalization of $1.86 billion, a PE ratio of -7.10 and a beta of -0.19. The company has a fifty day moving average of $30.39 and a 200-day moving average of $27.97. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. Akero Therapeutics, Inc. has a one year low of $15.32 and a one year high of $37.00.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.15). As a group, analysts expect that Akero Therapeutics, Inc. will post -3.96 EPS for the current year.

Analyst Ratings Changes

AKRO has been the topic of a number of recent research reports. Citigroup initiated coverage on shares of Akero Therapeutics in a research note on Monday, November 18th. They issued a “buy” rating and a $65.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a research report on Monday, November 18th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $46.83.

Institutional Trading of Akero Therapeutics

Hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in Akero Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after acquiring an additional 446 shares during the period. Eastern Bank purchased a new stake in shares of Akero Therapeutics during the 3rd quarter worth $100,000. Summit Financial Wealth Advisors LLC acquired a new position in shares of Akero Therapeutics during the 3rd quarter worth $205,000. Victory Capital Management Inc. purchased a new position in shares of Akero Therapeutics in the 3rd quarter valued at about $211,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Akero Therapeutics in the third quarter valued at about $265,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.